A randomized trial of ascorbic acid in polyposis coli

Henry J.R. Bussey, Jerome J. Decosse*, Eleanor E. Deschner, Anthony A. Eyers, Martin L. Lesser, Basil C. Morson, Sheila M. Ritchie, James P.S. Thomson, Jane Wadsworth

*Corresponding author for this work

Research output: Contribution to journalArticle

136 Citations (Scopus)


The possibility of pharmacological control of large bowel adenomas has been suggested by effectiveness of antioxidants in experimental tumor models and by the results of a limited clinical study using ascorbic acid. Over a two year period we tested this hypothesis in a randomized, double‐blind study of 49 patients with polyposis coli. Of 36 patients who were evaluable at completion, 19 had received ascorbic acid, 3g/day, and 17 had received a placebo. We found a reduction in polyp area in the ascorbic acid‐treated group at nine months of follow‐up (P < 0.03) and trends toward reduction in both number and area of rectal polyps during the middle of the trial. A labeling study of rectal epithelium with tritiated thymidine also hinted at a treatment effect. Our data suggest that ascorbic acid temporarily influenced polyp growth or turnover. Although these results have no current therapeutic value, our findings support continued studies of chemoprevention in this and other high risk settings.

Original languageEnglish
Pages (from-to)1434-1439
Number of pages6
Issue number7
Publication statusPublished - 1982
Externally publishedYes

Fingerprint Dive into the research topics of 'A randomized trial of ascorbic acid in polyposis coli'. Together they form a unique fingerprint.

Cite this